title: Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension.
abstract: Hypertension is common in patients with type 2 diabetes mellitus (DM), and contributes to the progression of its complications in patients with diabetes. Doxazosin is a selective alpha1-adrenoceptor-blocking anti-hypertensive agent and has a favorable impact upon lipid metabolism. We investigated the effect of doxazosin on the lipid metabolism in hypertensive patients with type 2 diabetes, especially low-density lipoprotein (LDL) particle size that is associated with many elements of the insulin resistance syndrome. Cross-sectional study (n=19) was designed to determine whether doxazosin, administered with an angiotensin II-converting enzyme inhibitor (ACEI) and a Ca antagonist, affects LDL particle size. As a follow-up study (n=6), lipid and glucose metabolism and LDL particle size were followed for 12 weeks before and after the initiation of doxazosin administration (1-4 mg/day). The average size of LDL particle was significantly larger in the patients treated with doxazosin (LDL-migration index (LDL-MI): 0.348+/-0.027) than those in the patient treated without doxazosin (0.378+/-0.035), although LDL cholesterol levels did not differ between the two groups. The plasma glucose and HbA1c levels remained unchanged. Lipid profile showed normolipemia throughout the period of the study. However, LDL particle size was demonstrated to become larger during the following period. Small LDL fraction (LDL3-7) diminished remarkably and large LDL (LDL1-2) increased on the polyacrylamide gel electrophoresis (PAGE) LDL system (LipoPrint). From this pilot study, it was concluded that doxazosin is a useful anti-hypertensive agent for hypertensive type 2 diabetic patients in improving the size of LDL particle.
authors.affiliation: Third Department of Internal Medicine, Hirosaki University School of Medicine, Zaifu-5, Hirosaki-shi, 036-8562, Aomori, Japan. tmsw@cc.hirosaki-u.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Tamasawa
authors.forename: J
authors.initials: J
authors.lastname: Matsui
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Gotoh
authors.forename: T
authors.initials: T
authors.lastname: Hinata
authors.forename: H
authors.initials: H
authors.lastname: Murakami
authors.forename: G J
authors.initials: GJ
authors.lastname: Zhi
authors.forename: T
authors.initials: T
authors.lastname: Suda
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D015992:Body Mass Index; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006441:Hemoglobin A / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL; D006441:Hemoglobin A; D017292:Doxazosin